About Modalis Therapeutics

Modalis is a biotech company that utilizes CRISPR technology to develop targeted therapeutics for genetic disorders, specifically focusing on conditions like congenital muscular dystrophy. Their approach aims to provide precise gene editing solutions to address the underlying genetic causes of these diseases.

```xml <problem> Genetic disorders like congenital muscular dystrophy lack effective treatments that address the underlying genetic mutations. Current therapeutic options often manage symptoms without correcting the root cause of the disease. This leaves a significant unmet need for targeted therapies that can precisely modify disease-causing genes. </problem> <solution> Modalis is developing CRISPR-based therapeutics to target and correct genetic mutations responsible for congenital muscular dystrophy and other genetic disorders. Their approach utilizes gene editing technology to precisely modify the disease-causing genes, offering the potential for long-lasting therapeutic effects. By directly addressing the genetic origin of these diseases, Modalis aims to provide more effective and potentially curative treatment options compared to traditional symptom management. Their lead candidate, MDL-101, is being developed as a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD). </solution> <features> - CRISPR-based gene editing technology for targeted correction of genetic mutations - Focus on developing therapeutics for genetic disorders, including congenital muscular dystrophy - Lead candidate, MDL-101, for the treatment of LAMA2-CMD - Aims to provide long-lasting therapeutic effects by directly addressing the genetic origin of diseases </features> <target_audience> The primary target audience includes patients suffering from genetic disorders, particularly congenital muscular dystrophy, and their families, as well as healthcare providers specializing in genetic diseases. </target_audience> ```

What does Modalis Therapeutics do?

Where is Modalis Therapeutics located?

Modalis Therapeutics is based in Tokyo, Japan.

When was Modalis Therapeutics founded?

Modalis Therapeutics was founded in 2016.

How much funding has Modalis Therapeutics raised?

Modalis Therapeutics has raised 25000000.

Location

Tokyo, Japan

Founded

2016

Funding

25000000

Employees

24 employees

Major Investors

UTokyo Innovation Platform

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Modalis Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

modalistx.com 3K+

Crunchbase

Founded 2016 – Tokyo, Japan

Funding

Estimated Funding

$20M+

Major Investors

UTokyo Innovation Platform

Team (20+)

No team information available.

Company Description

Problem

Genetic disorders like congenital muscular dystrophy lack effective treatments that address the underlying genetic mutations. Current therapeutic options often manage symptoms without correcting the root cause of the disease. This leaves a significant unmet need for targeted therapies that can precisely modify disease-causing genes.

Solution

Modalis is developing CRISPR-based therapeutics to target and correct genetic mutations responsible for congenital muscular dystrophy and other genetic disorders. Their approach utilizes gene editing technology to precisely modify the disease-causing genes, offering the potential for long-lasting therapeutic effects. By directly addressing the genetic origin of these diseases, Modalis aims to provide more effective and potentially curative treatment options compared to traditional symptom management. Their lead candidate, MDL-101, is being developed as a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).

Features

CRISPR-based gene editing technology for targeted correction of genetic mutations

Focus on developing therapeutics for genetic disorders, including congenital muscular dystrophy

Lead candidate, MDL-101, for the treatment of LAMA2-CMD

Aims to provide long-lasting therapeutic effects by directly addressing the genetic origin of diseases

Target Audience

The primary target audience includes patients suffering from genetic disorders, particularly congenital muscular dystrophy, and their families, as well as healthcare providers specializing in genetic diseases.